养阴清肺丸
Search documents
大批中成药将退出市场
21世纪经济报道· 2026-01-27 09:37
Core Viewpoint - The article discusses the impending regulatory changes in the Chinese traditional medicine sector, particularly the "death clause" for traditional Chinese medicine (TCM) products, which will lead to the elimination of over 70% of existing TCM approvals due to safety information issues by July 2026 [1][4]. Regulatory Changes - The National Medical Products Administration (NMPA) has implemented a new regulation that will not allow re-registration of TCM products if any safety information in their instructions remains "unclear" after three years from July 1, 2023 [1][4]. - As of 2025, multiple announcements have been made requiring TCM products to supplement core safety information, indicating a shift towards stricter regulatory compliance [3]. Industry Impact - The regulatory changes are expected to create a significant divide in the industry, with leading companies like Baiyunshan generating revenues of 61.606 billion yuan, while smaller firms struggle with revenues around 6 million yuan [4]. - The cost of compliance for smaller firms is estimated to be around 20 million yuan over three years, which could deplete their profits, while larger firms have the resources to manage these costs effectively [4]. Market Dynamics - The article predicts that 30% to 40% of TCM approvals will exit the market in the next 3-5 years, leading to a more concentrated market where only high-quality products with clinical value will survive [6][8]. - The regulatory framework is pushing for a transition from quantity to quality in the TCM industry, with a focus on clinical value and scientific evidence [8]. Strategic Responses - Companies are advised to focus on three main strategies: conducting real-world studies to supplement safety data, applying for new drug status for promising products, and voluntarily canceling low-value approvals to concentrate on core products [8]. - The future market will see increased entry barriers, with only products that demonstrate safety and clinical value being supported by insurance and procurement channels [8].
中成药再注册大考进入半年倒计时
2 1 Shi Ji Jing Ji Bao Dao· 2026-01-27 09:01
Core Viewpoint - The new regulations from the National Medical Products Administration (NMPA) regarding traditional Chinese medicine (TCM) registration are set to significantly impact the industry, with over 70% of existing TCM products potentially facing elimination due to safety information issues in their labeling [1][5]. Regulatory Changes - The "death clause" in the new regulations mandates that any TCM product with unclear safety information in its labeling will not be approved for re-registration after July 1, 2026 [1]. - The NMPA has already begun implementing these regulations, requiring several commonly used TCM products to supplement core safety information for re-registration [2]. - A new set of regulations for TCM production supervision will take effect on March 1, 2026, raising industry entry barriers and imposing stricter requirements on the entire supply chain [2]. Industry Dynamics - The TCM industry is experiencing a stark divide between leading enterprises and smaller firms, with significant revenue disparities; for instance, the top company, Baiyunshan, reported revenues of 61.606 billion yuan, while smaller firms averaged around 6 million yuan [3]. - The cost of compliance for smaller firms is substantial, with estimates suggesting that a traditional TCM product may require an investment of at least 20 million yuan over three years to meet safety data requirements [3]. - Leading companies like Yunnan Baiyao and Tongrentang are proactively streamlining their product lines and focusing on core products backed by clinical data, while many smaller firms are left with limited options [3][4]. Market Trends - The regulatory changes are expected to lead to a significant increase in industry concentration, with predictions that leading firms will retain over 70% of their core products, while mid-tier companies may lose half of their approvals within two years [4]. - A nationwide price regulation initiative is underway, targeting low-quality TCM products and establishing minimum treatment costs for various medications [4]. - The dual approach of safety data requirements and price regulation is anticipated to further compress the market for low-quality TCM products, pushing the industry towards a focus on quality over quantity [5]. Strategic Responses - TCM companies are advised to pursue three main strategies: conducting real-world studies to enhance safety data, reclassifying promising products as improved new drugs, and voluntarily canceling low-value approvals to concentrate on core offerings [6]. - The future TCM market is expected to see heightened entry barriers, with products lacking safety data losing market access, and reimbursement mechanisms favoring clinically valuable products [6]. - The ongoing regulatory overhaul is viewed as an opportunity for the industry to shed low-quality products and focus on those that can withstand scientific scrutiny and gain patient trust [6].
用科技赋能中医药发展
Bei Ke Cai Jing· 2025-11-18 01:44
Core Viewpoint - The article emphasizes the integration of traditional Chinese medicine (TCM) with modern technology and innovation, showcasing Tong Ren Tang's efforts in smart manufacturing, talent development, and sustained research and development (R&D) investments to enhance productivity and maintain its industry leadership [12]. Group 1: Smart Manufacturing - Tong Ren Tang has established multiple smart manufacturing production lines, including the first domestic online detection production line for large honey pills, demonstrating a commitment to technological advancement in TCM production [5][6]. - The Daxing factory has transitioned from digital smart production lines to data-driven smart workshops, utilizing real-time monitoring systems to enhance production efficiency and quality [5][6]. - The integration of AI algorithms allows for real-time monitoring of production parameters, improving overall product quality and standardization [5]. Group 2: Talent Development - The company recognizes the importance of talent in driving innovation and has implemented a dual-channel approach for talent acquisition and development, focusing on reducing internal inefficiencies [7]. - Tong Ren Tang has established a comprehensive training system for professional skills, covering various aspects of TCM production, and has actively participated in national skill competitions, achieving notable success [8]. - The company has also introduced a contractual management system for managerial positions to enhance organizational efficiency and foster a culture of innovation [7]. Group 3: Research and Development - During the 14th Five-Year Plan period, Tong Ren Tang has invested over 1.6 billion yuan in R&D, reinforcing its commitment to scientific innovation and the integration of industry, academia, and research [9]. - The company has established long-term collaborations with academic institutions and research teams to focus on new product development and post-market evaluation [10]. - Recent achievements include the registration of several products in Canada, indicating the company's expanding international presence and commitment to quality [11].
白露:秋凉渐至,正宜润补
Ren Min Ri Bao· 2025-09-05 07:25
Group 1 - The core idea of the articles revolves around the health implications and recommendations associated with the "White Dew" solar term, emphasizing the need for dietary and lifestyle adjustments to adapt to the changing weather conditions [1][2] - The article highlights the significance of "White Dew" as a transitional period into autumn and winter, where the focus should be on preventing dryness, nourishing the lungs, and maintaining warmth [2] - Recommendations for diet include increasing the intake of moistening foods such as pears, honey, and various herbs, while avoiding spicy and cold foods to prevent lung and spleen issues [1][2] Group 2 - Common health issues during the "White Dew" period include respiratory and digestive problems, with symptoms like dry throat, nasal bleeding, and dry skin being prevalent [2] - The article suggests remedies such as consuming lily and pear soup or herbal teas to alleviate symptoms, and emphasizes the importance of maintaining a balanced diet for those with weak digestive systems [2] - Emotional well-being is also addressed, with suggestions for outdoor activities and social interactions to combat the "autumn blues," promoting a positive mindset during this transitional season [2]